Report: Rare diseases are lucrative targets for drugmakers

08/23/2012 | PharmaTimes (U.K.)

Drugs to treat rare diseases are as economically viable as drugs to treat common diseases, thanks to incentives such as less-stringent clinical trial standards, according to a Thomson Reuters report. The data "substantiates the envisioned high returns on the R&D investment, particularly for drugs with multiple orphan disease approvals," said report co-author Kiran Meekings.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC